Decarboxy Moxifloxacin

CAS No. 1322062-57-6

Decarboxy Moxifloxacin( —— )

Catalog No. M26147 CAS No. 1322062-57-6

Decarboxylated moxifloxacin is a decarboxylated compound of moxifloxacin.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 89 In Stock
5MG 82 In Stock
10MG 122 In Stock
25MG 204 In Stock
50MG 298 In Stock
100MG 423 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Decarboxy Moxifloxacin
  • Note
    Research use only, not for human use.
  • Brief Description
    Decarboxylated moxifloxacin is a decarboxylated compound of moxifloxacin.
  • Description
    Decarboxylated moxifloxacin is a decarboxylated compound of moxifloxacin. Moxifloxacin is an oral active 8-methoxy quinolone antibiotic used in acute bacterial sinusitis, chronic bronchitis, acute bacterial deterioration, and community-acquired pneumonia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Trk
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1322062-57-6
  • Formula Weight
    357.429
  • Molecular Formula
    C20H24FN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H][C@]12CN(C[C@@]1([H])NCCC2)c1c(F)cc2c(c1OC)n(ccc2=O)C1CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Emiliano Cocco, et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.
molnova catalog
related products
  • SG-209

    SG 209 is an analog of nicorandil and acts as a K+ channel opener and nitrate-free coronary vasodilator.

  • NSP-SA-NHS

    NSP-SA-NHS is a chemiluminescent acridinium ester that can be used for immunoassays.

  • L524-0366

    L524-0366 is a TWEAK-Fn14 signaling cascade inhibitor.L524-0366 mitigated maladaptive remodeling with TAC. TWEAK induced secretion of the pro-inflammatory chemokine, monocyte chemoattractant protein 1 from WT but not Fn14-/-?fibroblasts in vitro, in part through activation of non-canonical NF-κB signaling.